Patents Assigned to The United States of America as represented by the Secretary, Department of Health and Human Services
  • Patent number: 11447797
    Abstract: The invention provides an adeno-associated viral (AAV) vector comprising a capsid comprising the amino acid sequence of SEQ ID NO: 4 or SEQ ID NO: 9, wherein the AAV vector further comprises a heterologous nucleic acid sequence, and wherein the heterologous nucleic acid sequence can encode the NGF-PTH fusion polypeptide or methylmalonyl CoA mutase enzyme. The invention also provides a polypeptide comprising nerve growth factor (NGF) signal peptide and parathyroid hormone (PTH), wherein the polypeptide can comprise, consist essentially of, or consist of the amino acid sequences of SEQ ID NO: 1 and SEQ ID NO: 2. The invention provides a nucleic acid encoding the polypeptide, a vector comprising the nucleic acid, and a composition comprising the polypeptide, nucleic acid, or vector, as well as treatment methods comprising the polypeptide, nucleic acid, vector, or composition.
    Type: Grant
    Filed: May 12, 2016
    Date of Patent: September 20, 2022
    Assignee: The United States of America,as represented by the Secretary, Department of Health and Human Service
    Inventors: John A. Chiorini, Giovanni Di Pasquale, Randy Chandler, Charles P. Venditti
  • Patent number: 11446238
    Abstract: Injectable hydrogels in the form of crosslinked nano beads or particle in the size range 5 nm to 10 ?m, comprising PAMAM dendrimer with asymmetrical peripheral end groups such that one of the terminal groups is involved in formation of hydrogel and the other in involved in the conjugation of drugs or imaging agents are formed by reaction of the PAMAM dendrimer with asymmetrical end groups with linear, branched, hyperbranched or star shaped polymers with functionalized terminal groups. The PAMAM dendrimer with asymmetrical terminal groups consists of a Generation 2 and above PAMAM dendrimer with symmetrical end groups modified using the amino acids or their modified forms. The gel is formed as small crosslinked particles in the size range 25 nm to 10 ?m and is suitable for injectable delivery of hydrogel or ocular delivery for the purpose of therapeutic treatment and imaging.
    Type: Grant
    Filed: September 27, 2016
    Date of Patent: September 20, 2022
    Assignees: Wayne State University, The United States of America, as Represented by the Secretary, Department of Health and Human Services
    Inventors: Kannan Rangaramanujam, Sujatha Kannan, Roberto Romero, Raghavendra Navath, Anupa Menjoge
  • Patent number: 11441122
    Abstract: The present is directed to compositions comprising regulatory T cell epitopes, wherein said epitopes comprise a polypeptide comprising at least a portion of SEQ NOS: 1-14, fragments and/or variants thereof, as well as methods of producing and using the same.
    Type: Grant
    Filed: October 5, 2018
    Date of Patent: September 13, 2022
    Assignees: EpiVax Inc., The United States of America, as Represented by the Secretary, Department of Health and Human Services Food and Drug Administration
    Inventors: William Martin, Amy S. Rosenberg
  • Patent number: 11440956
    Abstract: Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of thyroglobulin (TG), TG470-478. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of cancer in a mammal and methods of treating or preventing cancer in a mammal.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: September 13, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Kenichi Hanada, Qiong J. Wang, James C. Yang, Zhiya Yu
  • Patent number: 11440963
    Abstract: The invention provides a method of inhibiting a malignancy associated with human papilloma virus (HPV) comprising administering to a subject an agent that blocks PD-L1 and TGF-beta pathways, thereby inhibiting a malignancy associated with HPV in the subject.
    Type: Grant
    Filed: May 8, 2018
    Date of Patent: September 13, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Julius Y. Strauss, James L. Gulley, Christian S. Hinrichs
  • Patent number: 11441184
    Abstract: High efficiency methods for producing retinal pigment epithelial cells from induced pluripotent stem cells (iPSCs) are disclosed herein. The iPSCs are produced from somatic cells, including retinal pigment epithelial (RPE) cells, such as fetal RPE stem cells. In some embodiments, the iPSC include a tyrosinase promoter operably linked to a marker. Methods are disclosed for using the RPE cells, such as for treatment. Methods for screening for agents that affect RPE differentiation are also disclosed.
    Type: Grant
    Filed: September 27, 2019
    Date of Patent: September 13, 2022
    Assignee: THE UNITED STATES OF AMERICA, as represented by the Secretary, Department of Health and Human Services
    Inventors: Kapil Bharti, Janine Davis, Arvydas Maminishkis, Sheldon S. Miller
  • Publication number: 20220282208
    Abstract: Provided are methods of producing an isolated population of cells for adoptive cell therapy comprising use of at least one cell permeable Ca2+ dye. Further embodiments of the invention provide isolated populations of cells produced by the methods, related pharmaceutical compositions, and related methods of treating or preventing cancer in a patient.
    Type: Application
    Filed: September 18, 2020
    Publication date: September 8, 2022
    Applicant: THE UNITED STATES OF AMERICA,AS REPRESENTED BY THE SECRETARY,DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Douglas C. Palmer, Anna Pasetto, Nicholas P. Restifo, Steven A. Rosenberg
  • Patent number: 11434272
    Abstract: Disclosed is a synthetic T cell receptor (TCR) having antigenic specificity for an HLA-A2-restricted epitope of human papillomavirus (HPV) 16 E7, E711-19. Related polypeptides and proteins, as well as related nucleic acids, recombinant expression vectors, host cells, and populations of cells are also provided. Antibodies, or an antigen binding portion thereof, and pharmaceutical compositions relating to the TCRs of the invention are also provided. Also disclosed are methods of detecting the presence of a condition in a mammal and methods of treating or preventing a condition in a mammal, wherein the condition is cancer, HPV 16 infection, or HPV-positive premalignancy.
    Type: Grant
    Filed: November 23, 2020
    Date of Patent: September 6, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Christian S. Hinrichs, Steven A. Rosenberg
  • Patent number: 11434490
    Abstract: RNA aptamers are disclosed with distinct fluorescent properties, fluorophore binding affinities, and salt dependence. Also disclosed are corresponding fluorophores, with selected fluorophores evidencing high cellular permeability. The aptamer's high fluorophore affinities, the high brightness of the bound complexes, and their thermal and salt stability, provide distinct aspects of the disclosed aptamers.
    Type: Grant
    Filed: April 23, 2018
    Date of Patent: September 6, 2022
    Assignees: Centre National De La Recherche, Scientifique Université De Strasbourg, Simon Fraser University, The United States of America, As Represented by The Secretary, Department of Health and Human Services
    Inventors: Michael Ryckelynck, Alexis Autour, Peter Unrau, Elena Dolgosheina, Sunny Chiu Yuk Jeng, Shanker Shyam Sundhar Panchapakesan, Amir Abdolahzadeh, Razvan Cojocaru, Adrian Ferré D'Amaré, Robert Trachman
  • Patent number: 11428632
    Abstract: Systems and methods for three-dimensional fluorescence polarization excitation that generates maps of positions and orientation of fluorescent molecules in three or more dimensions are disclosed.
    Type: Grant
    Filed: May 31, 2018
    Date of Patent: August 30, 2022
    Assignee: THE UNITED STATES OF AMERICA, AS REPRESENTED BY THE SECRETARY, DEPARTMENT OF HEALTH AND HUMAN SERVICES
    Inventors: Hari Shroff, Abhishek Kumar, Shalin B. Mehta, Patrick Jean-La Riviere, Rudolf Oldenbourg, Yicong Wu, Talon Chandler
  • Patent number: 11426415
    Abstract: The present invention generally relates to compositions and methods for treating or preventing an endoplasmic reticulum stress disorder in subjects, including compositions and methods for treating or preventing Wolfram syndrome. The present invention also relates to methods for treating symptoms of neurodegenerative diseases.
    Type: Grant
    Filed: March 6, 2018
    Date of Patent: August 30, 2022
    Assignees: Washington University, The United States of America, As Represented by the Secretary, Department of Health and Human Services
    Inventors: Fumihiko Urano, Jana Mahadevan, Amy Clark, Ajit Jadhav, David Maloney, Brandon Harvey, Shyh-ming Yang, Mark Henderson
  • Patent number: 11421250
    Abstract: The invention provides for systems, methods, and compositions for targeting nucleic acids. In particular, the invention provides non-naturally occurring or engineered RNA-targeting systems comprising a novel RNA-targeting CRISPR effector protein and at least one targeting nucleic acid component like a guide RNA.
    Type: Grant
    Filed: December 16, 2017
    Date of Patent: August 23, 2022
    Assignees: The Broad Institute, Inc., Massachusetts Institute of Technology, President and Fellows of Harvard College, Rutgers, The State University of New Jersey, Skolkovo Institute of Science and Technology, The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Konstantin Severinov, Feng Zhang, Yuri I. Wolf, Sergey Shmakov, Ekaterina Semenova, Leonid Minakhin, Kira S. Makarova, Eugene Koonin, Silvana Konermann, Julia Joung, Jonathan S. Gootenberg, Omar O. Abudayyeh, Eric S. Lander
  • Patent number: 11415652
    Abstract: Multi-dimensional spectra associated with a specimen are reconstructed using lower dimensional spectra as constraints. For example, a two-dimensional spectrum associated with diffusivity and spin-lattice relaxation time is obtained using one-dimensional spectra associated with diffusivity and spin-lattice relaxation time, respectively, as constraints. Data for a full two dimensional spectrum are not acquired, leading to significantly reduced data acquisition times.
    Type: Grant
    Filed: August 11, 2017
    Date of Patent: August 16, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Peter J. Basser, Dan H. Benjamini
  • Publication number: 20220251536
    Abstract: Synthetic polynucleotides encoding human propionyl-CoA carboxylase alpha (synPCCA) and exhibiting augmented expression in cell culture and/or in a subject are described herein. Adeno-associated viral (AAV) gene therapy vectors encoding synPCCA successfully rescued the neonatal lethal phenotype displayed by propionyl-CoA carboxylase alpha (Pcca?/?) deficient mice, lowered circulating methylcitrate levels in the treated animals, and resulted in prolonged hepatic expression of the product of the synPCCA transgene in vivo.
    Type: Application
    Filed: June 26, 2020
    Publication date: August 11, 2022
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Charles P. Venditti, Randy J. Chandler
  • Patent number: 11407818
    Abstract: The present disclosure relates to polypeptides that specifically bind to Dengue virus non¬structural protein 1, including antibodies and fragments thereof. The antibody or antigen-binding fragment thereof may specifically bind Dengue virus (DENV) serotype 4 and include: a heavy chain variable region that comprises at least one CDR amino acid sequence selected from the group consisting of: SGYNWH, YIH YS GGTN YNPS LKS, RTGTVPFAY, SYVMH, YLNPYNDDTKYNEKFKG, and GPPYALDY. The present disclosure further relates to methods of producing the polypeptides of the present disclosure, methods of diagnosing DENV, and methods of treating a DENV infection.
    Type: Grant
    Filed: June 22, 2017
    Date of Patent: August 9, 2022
    Assignee: The United States of America, as Represented By The Secretary, Department of Health and Human Services
    Inventors: Elizabeth Anne Hunsperger, Tesfaye Gelanew Taye
  • Patent number: 11401503
    Abstract: An embodiment of the invention provides a method of promoting regression of cancer in a mammal comprising obtaining a tumor tissue sample from the mammal; culturing the tumor tissue sample in a first gas permeable container containing cell medium therein; obtaining tumor infiltrating lymphocytes (TIL) from the tumor tissue sample; expanding the number of TIL in a second gas permeable container containing cell medium therein using irradiated allogeneic feeder cells and/or irradiated autologous feeder cells; and administering the expanded number of TIL to the mammal. Methods of obtaining an expanded number of TIL from a mammal for adoptive cell immunotherapy are also provided.
    Type: Grant
    Filed: December 6, 2018
    Date of Patent: August 2, 2022
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, Wilson Wolf Manufacturing Corporation
    Inventors: Steven A. Rosenberg, Mark E. Dudley, David Stroncek, Marianna Sabatino, Jianjian Jin, Robert Somerville, John R. Wilson
  • Patent number: 11400150
    Abstract: The present invention relates to attenuated, immunogenic West Nile virus chimeras built on a dengue virus backbone for the production of immunogenic, live, attenuated West Nile virus vaccines,
    Type: Grant
    Filed: November 19, 2020
    Date of Patent: August 2, 2022
    Assignees: The United States of America, as represented by the Secretary, Department of Health and Human Services, The Government of the United States, as Represented by The Secretary of The Army
    Inventors: Alexander G. Pletnev, Joseph R. Putnak, Robert M. Chanock, Brian R. Murphy, Stephen S. Whitehead, Joseph E. Blaney
  • Patent number: 11401544
    Abstract: Methods and kits for preparing re-usable single cells are described. Cell components are anchored using a nano-scale scaffold to create a re-usable single cell. The nano-scale scaffold may be a polyacrylamide nano-scale scaffold. Methods to determine modifications of the genome, transcriptome, or epigenome are described.
    Type: Grant
    Filed: May 4, 2018
    Date of Patent: August 2, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Giovanna Tosato, Hidetaka Ohnuki
  • Publication number: 20220227853
    Abstract: Antibodies and antigen binding fragments that specifically bind to P. falciparum circumsporozoite protein are disclosed. Nucleic acids encoding these antibodies, vectors and host cells are also provided. The disclosed antibodies, antigen binding fragments, nucleic acids and vectors can be used, for example, to inhibit a P. falciparum infection.
    Type: Application
    Filed: May 4, 2020
    Publication date: July 21, 2022
    Applicant: The United States of America,as represented by the Secretary,Department of Health and Human Services
    Inventors: Robert Seder, Lawrence Wang, Rachel Vistein, Joseph Francica
  • Patent number: 11390683
    Abstract: Polypeptides and proteins that specifically bind to and immunologically recognize human mesothelin582-598 (IP-NGYLVLDLSMQEALS) (SEQ ID NO: 1) are disclosed. Anti-mesothelin binding moieties, nucleic acids, recombinant expression vectors, host cells, populations of cells, pharmaceutical compositions, and conjugates relating to the polypeptides and proteins are disclosed. Methods of reducing mesothelin shed from cell membranes, methods of reducing the activity of TNF? converting enzyme, methods of detecting the presence of cancer, and methods of treating or preventing cancer are also disclosed.
    Type: Grant
    Filed: May 17, 2018
    Date of Patent: July 19, 2022
    Assignee: The United States of America, as represented by the Secretary, Department of Health and Human Services
    Inventors: Ira H. Pastan, Masanori Onda, Tapan Bera, Mitchell Ho